Compare · GILD vs KYMR
GILD vs KYMR
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and KYMR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 17.5x KYMR ($9.52B).
- Over the past year, GILD is up 24.1% and KYMR is up 150.4% - KYMR leads by 126.4 points.
- KYMR has been more active in the news (42 items in the past 4 weeks vs 7 for GILD).
- Both have 25 recent analyst ratings on file.
- Company
- Gilead Sciences Inc.
- Kymera Therapeutics Inc.
- Price
- $134.23-1.50%
- $115.69+1.52%
- Market cap
- $166.72B
- $9.52B
- 1M return
- +5.49%
- +32.60%
- 1Y return
- +24.06%
- +150.41%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2020
- News (4w)
- 7
- 42
- Recent ratings
- 25
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest KYMR
- Chief Executive Officer Mainolfi Nello exercised 50,000 shares at a strike of $2.08 and sold $5,950,000 worth of shares (50,000 units at $119.00) as part of a pre-agreed trading plan (SEC Form 4)
- Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
- Chief Business Officer Goodman Noah sold $387,329 worth of shares (3,389 units at $114.29) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 47,179 units (SEC Form 4)
- Chief Financial Officer Jacobs Bruce N. exercised 61,378 shares at a strike of $5.33 and sold $8,864,829 worth of shares (77,109 units at $114.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 244,883 units (SEC Form 4)
- Chief Executive Officer Mainolfi Nello sold $9,223,527 worth of shares (80,000 units at $115.29) as part of a pre-agreed trading plan and exercised 80,000 shares at a strike of $2.08 (SEC Form 4)
- Amendment: Director Booth Bruce sold $8,281,905 worth of shares (76,650 units at $108.05) as part of a pre-agreed trading plan (SEC Form 4)
- Director Booth Bruce sold $3,424,800 worth of shares (31,283 units at $109.48) as part of a pre-agreed trading plan (SEC Form 4)
- Director Booth Bruce sold $56,460,136 worth of shares (513,245 units at $110.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Kymera Therapeutics Inc.
- SEC Form 144 filed by Kymera Therapeutics Inc.